Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action -Hagens Berman
11 déc. 2023 12h19 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action - Hagens Berman
07 déc. 2023 09h04 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
SLRN Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
07 déc. 2023 08h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress - Hagens Berman
04 déc. 2023 15h00 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
04 déc. 2023 08h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
HAGENS BERMAN Alerts Acelyrin (SLRN) Investors to Pending Securities Fraud Class Action, Encourages Investors Who Suffered Substantial Losses to Contact Firm’s Attorneys
01 déc. 2023 13h19 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
30 nov. 2023 16h30 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acelyrin (SLRN) Investors with Substantial Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed
27 nov. 2023 09h27 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate’s Progress-Hagens Berman
20 nov. 2023 11h01 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress-Hagens Berman
16 nov. 2023 18h42 HE
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period:...